Stock Analysis on Net

Eli Lilly & Co. (NYSE:LLY)

$24.99

Analysis of Liquidity Ratios

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Liquidity Ratios (Summary)

Eli Lilly & Co., liquidity ratios

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Current ratio
Quick ratio
Cash ratio

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).


The liquidity position, as indicated by the presented ratios, demonstrates fluctuating performance over the five-year period. A general trend of initial decline followed by improvement is observable across all measured ratios. The period between 2021 and 2023 shows weakening liquidity, while 2024 and 2025 exhibit signs of strengthening.

Current Ratio
The current ratio decreased from 1.23 in 2021 to a low of 0.94 in 2023, suggesting a diminishing ability to cover short-term liabilities with short-term assets. However, the ratio rebounded to 1.15 in 2024 and further increased to 1.58 in 2025, indicating improved short-term solvency. This recovery suggests positive changes in the composition of current assets or current liabilities.
Quick Ratio
The quick ratio followed a similar pattern to the current ratio, declining from 0.79 in 2021 to 0.52 in 2023. This indicates a weakening ability to meet short-term obligations with the most liquid assets. The quick ratio then increased to 0.58 in 2024 and 0.78 in 2025, mirroring the improvement seen in the current ratio, though remaining below the 2021 level. The increase suggests improved liquidity excluding inventory.
Cash Ratio
The cash ratio experienced the most pronounced decline, falling from 0.25 in 2021 to 0.10 in 2023. This signifies a substantial reduction in the proportion of current assets held as cash. A slight recovery was observed in 2024, remaining at 0.12, followed by a more notable increase to 0.21 in 2025. This suggests a rebuilding of cash reserves towards the end of the period.

Overall, the observed trends suggest a period of liquidity challenges between 2021 and 2023, followed by a recovery and strengthening of the liquidity position in 2024 and 2025. The increasing ratios across all measures indicate a positive shift in the company’s ability to meet its short-term obligations.


Current Ratio

Eli Lilly & Co., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Current assets
Current liabilities
Liquidity Ratio
Current ratio1
Benchmarks
Current Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Current Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The current ratio exhibited fluctuations over the five-year period. Initially, the ratio decreased before recovering and ultimately demonstrating substantial growth.

Current Ratio Trend
The current ratio began at 1.23 in 2021, indicating the company possessed $1.23 of current assets for every $1.00 of current liabilities. A decline was observed in 2022, with the ratio falling to 1.05. This downward trend continued into 2023, reaching a low of 0.94, suggesting a potential weakening in short-term liquidity. However, the ratio began to improve in 2024, rising to 1.15, and experienced significant growth in 2025, reaching 1.58. This represents a substantial increase in the company’s ability to cover its short-term obligations with its current assets.

The increase in the current ratio in the later years is attributable to a faster rate of growth in current assets compared to current liabilities. While both current assets and current liabilities increased throughout the period, the acceleration in current asset growth, particularly in 2025, drove the improvement in the ratio.

Asset and Liability Changes
Current assets increased from US$18,452 million in 2021 to US$55,629 million in 2025. Current liabilities also increased, moving from US$15,053 million in 2021 to US$35,228 million in 2025. The relative increase in current assets, especially in the final two years, is the primary driver of the observed improvement in the current ratio.

The movement in the current ratio suggests a changing liquidity position. The initial decline raised potential concerns, but the subsequent recovery and strong growth indicate improved short-term financial health.


Quick Ratio

Eli Lilly & Co., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Accounts receivable, net of allowances
Other receivables
Total quick assets
 
Current liabilities
Liquidity Ratio
Quick ratio1
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Quick Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The quick ratio exhibited fluctuations over the five-year period. Initially, the ratio decreased before stabilizing and then increasing again. A review of the underlying components, total quick assets and current liabilities, provides further insight into these movements.

Overall Trend
The quick ratio began at 0.79 in 2021, declined to a low of 0.52 in 2023, and then showed improvement, reaching 0.78 in 2025. This indicates a period of weakening short-term liquidity followed by a recovery.
Quick Ratio Decline (2021-2023)
The decrease in the quick ratio from 2021 to 2023 was primarily driven by a faster growth rate in current liabilities compared to total quick assets. While quick assets decreased from 2021 to 2022, they increased in subsequent years. However, current liabilities consistently increased throughout the entire period, outpacing the growth in quick assets until 2025.
Quick Ratio Stabilization and Improvement (2023-2025)
From 2023 to 2025, the quick ratio began to recover. This was due to a significant increase in total quick assets, rising from US$14,155 million to US$27,423 million. Although current liabilities continued to increase, the rate of increase slowed, allowing quick assets to catch up and improve the ratio.
Component Analysis
Total quick assets demonstrated a substantial increase in the later years of the period, suggesting improved liquidity in terms of readily convertible assets. Current liabilities consistently increased, indicating growing short-term obligations. The interplay between these two components determined the overall trend in the quick ratio.

The observed fluctuations in the quick ratio suggest changes in the company’s short-term financial position. The recovery in 2024 and 2025 is a positive sign, but continued monitoring of both quick assets and current liabilities is warranted.


Cash Ratio

Eli Lilly & Co., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2025 Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Selected Financial Data (US$ in millions)
Cash and cash equivalents
Total cash assets
 
Current liabilities
Liquidity Ratio
Cash ratio1
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences
Cash Ratio, Industry
Health Care

Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).

1 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =

2 Click competitor name to see calculations.


The cash ratio exhibited fluctuations over the five-year period. Initially, the ratio decreased before stabilizing and then increasing again. Total cash assets and current liabilities both experienced changes throughout the period, influencing the cash ratio’s trajectory.

Cash Ratio Trend
The cash ratio began at 0.25 in 2021, indicating the company held 25 cents of cash for every dollar of current liabilities. A significant decline was observed in 2022, with the ratio falling to 0.12. This downward trend continued into 2023, reaching a low of 0.10. The ratio remained relatively stable in 2024 at 0.12 before increasing to 0.21 in 2025.
Total Cash Assets
Total cash assets decreased from US$3,819 million in 2021 to US$2,067 million in 2022. A partial recovery occurred in 2023, with cash assets rising to US$2,819 million. Further increases were noted in 2024 (US$3,268 million) and a substantial increase in 2025, reaching US$7,268 million.
Current Liabilities
Current liabilities demonstrated a consistent upward trend throughout the period. Starting at US$15,053 million in 2021, they increased to US$17,138 million in 2022. This growth continued in subsequent years, reaching US$27,293 million in 2023, US$28,377 million in 2024, and US$35,228 million in 2025.

The initial decline in the cash ratio from 2021 to 2023 was likely driven by a combination of decreasing cash assets and increasing current liabilities. The stabilization in 2024 suggests a potential balance between these two factors. The substantial increase in the cash ratio in 2025 is attributable to the significant growth in total cash assets, outpacing the increase in current liabilities.